MARKET

DRRX

DRRX

DURECT
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.100
-0.070
-3.23%
After Hours: 2.130 +0.03 +1.43% 18:23 07/10 EDT
OPEN
2.180
PREV CLOSE
2.170
HIGH
2.180
LOW
2.020
VOLUME
1.03M
TURNOVER
--
52 WEEK HIGH
3.949
52 WEEK LOW
0.6400
MARKET CAP
411.65M
P/E (TTM)
-16.5354
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average DRRX stock price target is 4.525 with a high estimate of 6.00 and a low estimate of 2.100.

EPS

DRRX News

More
Is It Too Late to Buy These 3 Pharmaceutical Stocks?
Motley Fool · 3d ago
DURECT Corporation Announces Initiation of Patient Recruitment in Phase 2 Safety and Efficacy Study of DUR-928 in COVID-19 Patients with Acute Liver or Kidney Injury
PR Newswire · 07/01 13:30
U.S. FDA seeks more data on Heron Therapeutics' non-opioid painkiller
Reuters · 06/29 14:00
DURECT Reports Joined Russell 3000 Index On Jun. 29
Benzinga · 06/29 12:51
DURECT Corporation Joins the Russell 3000® Index
DURECT Corporation (Nasdaq: DRRX) today announced that it is set to join the broad-market Russell 3000® Index as a result of the 2020 Russell indexes annual reconstitution, effective after the US stock market opens today, June 29, 2020.
PR Newswire · 06/29 12:30
Gilead terminates agreement with DURECT
Seeking Alpha - Article · 06/26 21:34
Gilead Terminates License Agreement for Long-Acting Injectable HIV Investigational Product
DURECT Corporation (Nasdaq: DRRX) today announced that Gilead Sciences, Inc., (Gilead) has provided notice that, effective as of December 22, 2020, it is terminating the License Agreement dated July 19, 2019 and a related R&D; agreement between Gilead and DURE
PR Newswire · 06/26 21:15
DURECT Corporation (DRRX): Hedge Funds Are Nibbling
Insider Monkey · 06/26 15:37

Industry

Biotechnology & Medical Research
-0.77%
Pharmaceuticals & Medical Research
-0.48%

Hot Stocks

Symbol
Price
%Change

About DRRX

Durect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic. The Company's ALZET product line consists of miniature, implantable osmotic pumps and accessories used for experimental research in mice, rats and other laboratory animals. The Company also manufactures and sells osmotic pumps used in laboratory research and design; and develops and manufactures a range of standard and custom biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products.
More

Webull offers kinds of DURECT Corporation stock information, including NASDAQ:DRRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DRRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DRRX stock methods without spending real money on the virtual paper trading platform.